SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 1029
  • 2
    Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH. Prostate cancer: a serious disease suitable for prevention. BJU Int 2009; 103: 86470
  • 3
    Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 6670
  • 4
    Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal 2010; 10: 191931
  • 5
    Guazzoni G, Nava L, Lazzeri M et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60: 21422
  • 6
    Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001; 7: 84653
  • 7
    Garbis SD, Roumeliotis T et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008; 7: 314658
  • 8
    Henshall SM, Horvath LG, Quinn DI et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98: 14204
  • 9
    Schröder FH, Hugosson J, Roobol MJ et al. ERSPC investigators. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360: 13514
  • 10
    Andriole GL, Grubb RL 3rd, Buys SS et al. PLCO Project Team. Mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009; 360: 13109
  • 11
    Eckersberger E, Finkelstein J, Sadri H et al. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol 2009; 11: 12733
  • 12
    Bondar OP, Barnidge DR, Klee EW, Davis BJ, Klee GG. LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem 2007; 53: 6738
  • 13
    Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998; 58: 235963
  • 14
    Byrne JC, Downes MR, O'Donoghue N et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009; 8: 94257
  • 15
    O'Hurley G, O'Grady A, Smyth P et al. Evaluation of zinc-alpha-2-glycoprotein and proteasome subunit beta-type 6 expression in prostate cancer using tissue microarray technology. Appl Immunohistochem Mol Morphol 2010; 18: 5127
  • 16
    Descazeaud A, Taille A, Allory Y et al. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006; 66: 103743
  • 17
    Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 799800
  • 18
    Schostak M, Schwall GP, Poznanović S et al. Annexin A3 in urine: a highly specific non invasive marker for prostate cancer early detection. J Urol 2009; 181: 34353
  • 19
    Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of MPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13: 51038